Very bullish recent price action on ACW - ASX. Closing above the...

Very bullish recent price action on ACW - ASX. Closing above the 20,50,100, and 200 day moving averages. MACD indicator also building positive momentum. Previous price gap at 6.5c will act like a magnet to be filled.





Bigger picture on fundamental value. IMO Actinogen (ACW -ASX) easily worth multiples of todays value based on :

1. Peer review papers highlighting effectiveness in treating those with elevated p Tau for Alzeihmers Disease (AD)
2. Results and safety profile from the previous 400 patients dosed with Xanamem,
3. Ongoing FDA discussions and the potential for Xanamem to treat MDD (depression) and other neurological disorders (i.e., Parkinson's Disease)
4. Alzeihmers Disease market size (i.e., over $12 bn USD in years to come) growing at a CAGR of over 10%p.a.,
5. Huge unmet need
6. Late stage in the clinical trial cycle i.e., phase 2b/3
7. Appointment of personal to specifically commercialise the drug (i.e., Andy Udell)
8. Research papers i.e., Edison Research
9. Broker Upgrades
10. Flaws in existing amyloid treatment alternatives (i.e, Leqembi's side effects)
11. Ongoing discussions with interested parties, and
12. Recent multi billion dollar sales for drugs treating depression schizophrenia and other neurological disorders e.g., J&J and Intra Cellular


DYOR Opinions Only